Evaluation of effect of OMEGA3 supplement on the incidence of gestational diabetes mellitus in high risk pregnancies for diabetes
Phase 3
Recruiting
- Conditions
- Gestational Diabetes.Gestational diabetes mellitusO24.4
- Registration Number
- IRCT20200505047306N1
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 70
Inclusion Criteria
Women 18 to 22 weeks diagnosed with high-risk pregnancies
Exclusion Criteria
Diagnosis of overt diabetes or use of insulin at baseline (FBS> = 105 or 2 hpp> = 120)
Dissatisfaction with the company in studying the history of allergies to omega-3
Unable to continue taking the drug due to digestive problems or allergic reactions
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The incidence of gestational diabetes in the Omega-3 group. Timepoint: In the time before and 6 weeks after taking the supplement. Method of measurement: Lab report.
- Secondary Outcome Measures
Name Time Method Blood sugar levels in the supplement and placebo groupplacebo group. Timepoint: In the time before and 6 weeks after consumption. Method of measurement: Lab report.;Insulin levels in the placebo and omega groupsinsulin levels in both groups. Timepoint: In the time before and 6 weeks after consumption. Method of measurement: Lab report.;HOMA-IR and HOMA-B in two groups of omega-3 and placebo supplements. Timepoint: In the time before and 6 weeks after consumption. Method of measurement: Lab report.;Fat profile in two groups of omega-3 and placebo supplements. Timepoint: In the time before and 6 weeks after consumption. Method of measurement: Lab report.